secwatch.observer — SEC 8-K summary
======================================

Issuer:     Janux Therapeutics, Inc. (JANX)
CIK:        0001817713
Form:       8-K
Filed at:   2023-05-09T23:59:59+00:00
Accession:  0000950170-23-019856
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Janux Therapeutics enters into $150M ATM equity offering agreement with BofA
----------------------------------------------------------------------------

- Up to $150M in common stock may be sold at the company's discretion through BofA as sales agent or principal.
- BofA will receive up to 3% commission on gross proceeds; company also reimburses certain legal fees.
- Sales may occur via negotiated transactions, block trades, or at-the-market on Nasdaq.
- The offering is under an existing S-3 registration statement; no obligation to sell any shares.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1817713/000095017023019856/0000950170-23-019856-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1817713/000095017023019856/janx-20230509.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-019856

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer